Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPY1R | P25929 | 6/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.38 |
| ▸ | CXCR4 | P61073 | 4/20 | 0.38 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4887081 | 1.00 | KDM1A (0.42) | KDM1AADORA2AHDAC1HDAC6ALDH1A1 | |
| SCHEMBL14566706 | 1.00 | KDM1A (0.42) | KDM1AADORA2AHDAC1HDAC6ALDH1A1 | |
| SCHEMBL4068879 | 1.00 | KDM1A (0.42) | KDM1AADORA2AHDAC1HDAC6ALDH1A1 | |
| SCHEMBL20848115 | 0.87 | GAA (0.47) | ADORA2AHDAC1HDAC6ALDH1A1KMT2A | |
| SCHEMBL13069026 | 0.87 | GAA (0.47) | ADORA2AHDAC1HDAC6ALDH1A1KMT2A | |
| SCHEMBL4882672 | 0.81 | HDAC1 (0.48) | ADORA2AHDAC1HDAC6CXCR4 | |
| SCHEMBL4113740 | 0.81 | HDAC1 (0.48) | ADORA2AHDAC1HDAC6CXCR4 | |
| SCHEMBL4175835 | 0.80 | KDM1A (0.35) | KDM1AADORA2AALDH1A1KMT2AMEN1 | |
| SCHEMBL30239411 | 0.78 | KDM1A (0.41) | KDM1AALDH1A1NPY1RSLC6A4KCNH2 | |
| SCHEMBL14037709 | 0.78 | HDAC1 (0.64) | KDM1AADORA2AHDAC1HDAC6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024216075-A1 | SYNTHESIS OF MAVORIXAFOR AND INTERMEDIATES THEREOF | X4 PHARMACEUTICALS, INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| US-20210009557-A1 | ACYCLIC CXCR4 INHIBITORS AND USES THEREOF | X4 PHARMACEUTICALS, INC. | 2021-01-14 | — | — | US | disclosed |
| US-20100280010-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2010-11-04 | — | — | US | disclosed |
| US-20100280010-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2010-11-04 | — | — | US | disclosed |
| EP-1487795-B1 | SYNTHESIS OF ENANTIOMERICALLY PURE AMINO-SUBSTITUTED FUSED BICYCLIC RINGS | ANORMED INC (CA) | 2010-11-03 | — | — | EP | disclosed |
| US-20100227880-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2010-09-09 | — | — | US | disclosed |
| EP-1919872-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2009-08-05 | — | — | EP | disclosed |
| EP-1778231-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2009-06-03 | — | — | EP | disclosed |
| EP-1984376-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2009-04-08 | — | — | EP | disclosed |
| US-7452994-B2 | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | ANORMED, INC. (CA) | 2008-11-18 | — | — | US | disclosed |
| US-20070254910-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2007-11-01 | — | — | US | disclosed |
| US-20070232615-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-20070232615-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2007-10-04 | — | — | US | disclosed |
| WO-2007087549-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-08-02 | — | — | WO | disclosed |
| EP-1789045-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-30 | — | — | EP | disclosed |
| EP-1778231-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20070060757-A1 | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | ANORMED INC. (CA) | 2007-03-15 | — | — | US | disclosed |
| WO-2007027999-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-08 | — | — | WO | disclosed |
| WO-2006023400-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-02 | — | — | WO | disclosed |
| WO-2006020415-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280010-A1 | CHEMICAL COMPOUNDS | CCR5, CXCR4, CXCR3 | KDM1A 4575/4885ADORA2A 370/4885HDAC1 844/4885 |
| US-20100227880-A1 | CHEMICAL COMPOUNDS | CYP3A5, SLC10A1, ABCB11 | KDM1A 3157/4885ADORA2A 3131/4885HDAC1 1454/4885 |
| US-20210009557-A1 | ACYCLIC CXCR4 INHIBITORS AND USES THEREOF | CXCR4, CXCR3, CXCR1 | KDM1A 4114/4885ADORA2A 88/4885HDAC1 551/4885 |
| US-20070060757-A1 | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | CBR1, POR, CBR3 | KDM1A 1500/4885ADORA2A 832/4885HDAC1 2323/4885 |
| US-20070232615-A1 | Chemical Compounds | CXCR4, CCR5, CXCR3 | KDM1A 4512/4885ADORA2A 388/4885HDAC1 815/4885 |
| US-20070254910-A1 | CHEMICAL COMPOUNDS | CXCR4, CCR5, CXCR3 | KDM1A 4512/4885ADORA2A 388/4885HDAC1 815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.